Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label, Phase 1b Study of ACP-196 With and Without Dexamethasone in Subjects With Multiple Myeloma

Next Previous
Trial Profile

An Open-Label, Phase 1b Study of ACP-196 With and Without Dexamethasone in Subjects With Multiple Myeloma

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 06 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Acalabrutinib (Primary) ; Dexamethasone
  • Indications Multiple myeloma
  • Focus Adverse reactions
  • Sponsors Acerta Pharma

Most Recent Events

  • 21 Jun 2020 Results (N=1040) of pooled analysis from nine clinical studies: ACE-CL-007, ACE-CL-309, ACE-CL-001, 15-H-0016, ACE-LY-002, ACE-LY-003, ACE-LY-004, ACE-MY-001, ACE-WM-001 assessing safety profile of acalabrutinib monotherapy in multiple B-cell malignancies presented at the 25th Congress of the European Haematology Association
  • 18 Jun 2019 Status changed from active, no longer recruiting to completed.
  • 17 Dec 2018 Results of population pharmakoinetics of Acalabrutinib and its Active Metabolite using data from this and other 12 studies, published in the Clinical Pharmacokinetics

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top